Home › Research › Treatments
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ.. The Cochrane database of systematic reviews, 2021-02-22
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia. There are currently no pharmacological treatments recommended for improving either cognition or function in people with VCI. Three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are licenced for the treatment of dementia due to Alzheimer's disease.
What this study adds
Evidence grade: High
This is a pooled review of 2,193 participants. This network meta-analysis examined whether three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) improve cognition or function in people with vascular cognitive impairment. Reported effect size: OR 1.95; OR 3.21; OR 1.57.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Battle, C. E., Abdul-Rahim, A. H., Shenkin, S. D., Hewitt, J., & Quinn, T. J. (2021). Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. The Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd013306.pub2
Vancouver
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. The Cochrane database of systematic reviews. 2021. doi:10.1002/14651858.cd013306.pub2. PMID: 33704781.
BibTeX
@article{battle2021-33704781,
author = {Battle, C. E. and Abdul-Rahim, A. H. and Shenkin, S. D. and Hewitt, J. and Quinn, T. J.},
title = {{Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis}},
journal = {The Cochrane database of systematic reviews},
year = {2021},
doi = {10.1002/14651858.cd013306.pub2},
pmid = {33704781},
url = {https://doi.org/10.1002/14651858.cd013306.pub2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There are currently no pharmacological treatments recommended for improving either cognition or function in people with VCI.
- Three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are licenced for the treatment of dementia due to Alzheimer's disease.
- They are thought to work by compensating for reduced cholinergic neurotransmission, which is also a feature of VCI.
- Through pairwise comparisons with placebo and a network meta-analysis, we sought to determine whether these medications are effective in VCI and whether there are differences between them with regard to efficacy or adverse events.
Why it matters
This network meta-analysis examined whether three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) improve cognition or function in people with vascular cognitive impairment. It addresses treatment of vascular cognitive impairment, not Alzheimer's disease, and does not establish a cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants2,193
- Effect sizeOR 1.95; OR 3.21; OR 1.57
- Evidence strengthHigh
How this study scored 77/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. We have no data on senior author's track record, so that was left out: it earned 74 of the 96 points we could judge it on, which is 77 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Cochrane database of systematic reviews) |
| Journal's citation record | 3 / 4 | Cochrane Database of Systematic Reviews: journal h-index 468 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,193 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 123 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 17.6 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 4 / 6 | Cited 11.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 3 / 4 | Cited 70 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Glasgow: institution h-index 1,600 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33704781) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 74 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 74 of the 96 points we could judge it on is 77 out of 100. |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/14651858.cd013306.pub2
- PubMed: 33704781
- Original source →
- Free full text: ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.